PulmoStem

AmnioPul-02 (PulmoStem) is an allogeneic, lung-specific mesenchymal stem cell (MSC) therapy derived from human amniotic fluid. Developed by the Swedish biopharmaceutical company Amniotics AB, the therapy consists of neonatal-quality MSCs selected for their high proliferative capacity and specific lung-homing properties. It is primarily being developed to treat inflammatory and fibrotic lung conditions, including COVID-19-related Acute Respiratory Distress Syndrome (ARDS) and other viral lower respiratory tract infections. The cells function by secreting immunomodulatory and anti-inflammatory factors that reduce pulmonary inflammation and promote tissue regeneration, potentially preventing the progression to chronic lung fibrosis. The therapy is administered via intravenous infusion.

Brand names

PulmoStem

Other names

AmnioPul-02AmnioPul02AmnioPul 02